YSB's revenue for the
six
months ended in Dec. 2023 was HK$9,848 Mil.
Its revenue for the trailing twelve months (TTM) ended in Dec. 2023 was HK$18,564 Mil.
YSB's Revenue per Share for the
six
months ended in Dec. 2023 was HK$15.38.
Its Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 was HK$80.56.
During the past 12 months, the average Revenue per Share Growth Rate of YSB was 90.70% per year.
During the past 3 years, the average Revenue per Share Growth Rate was 61.70% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get other companies' revenue growth rate using Revenue per Share data.
During the past 4 years, YSB's highest 3-Year average Revenue per Share Growth Rate was 61.70% per year. The lowest was 61.70% per year. And the median was 61.70% per year.
YSB Revenue Historical Data
The historical data trend for YSB's Revenue can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Pharmaceutical Retailers subindustry, YSB's Revenue, along with its competitors' market caps and Revenue data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
YSB's Revenue Distribution in the Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, YSB's Revenue distribution charts can be found below:
* The bar in red indicates where YSB's Revenue falls into.
YSB Revenue Calculation
Also referred as sales, revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top.
Revenue for the trailing twelve months (TTM) ended in Dec. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was HK$18,564 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
YSB (HKSE:09885) Revenue Explanation
In ranking the predictability, companies with more consistent revenue and earnings growth are ranked high with predictability.
Peter Lynch categorized companies according to their revenue growth:
His favorite companies are stalwart, those growing between 10-20% a year.
Companies in cyclical industries may see their revenue fluctuate wildly in good years and bad years.
Be Aware
Revenue can be manipulated by changing the way how revenue is booked. Companies may book sales before the payment is received, or before the revenue is fully earned. These will be added to balance sheet items such as account payable or account receivables.
YSB Revenue Related Terms
Thank you for viewing the detailed overview of YSB's Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.
YSB Inc is a digital pharmaceutical platform serving businesses outside of hospitals in China. The Company is committed to using digitalization to empower participants in the out-of-hospital pharmaceutical market, including pharmaceutical companies, distributors, vendors, pharmacies and primary healthcare institutions, and strives to bring pharmaceutical health products and services to the downstream safely and efficiently, so that users can easily obtain a large number of comprehensive and high-quality drugs at a fair and transparent price. It has turned the process of pharmaceutical transaction and service into a digitalized, standardized and scalable one.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
HKSE:09885 has been successfully added to your